About the Authors

Thuy T. Le

Affiliation Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Kresten Skak

Affiliation Leo Pharma, Copenhagen, Denmark

Kate Schroder

Affiliation Inflammasome Laboratory, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, Queensland, Australia

Wayne A. Schroder

Affiliation Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Glen M. Boyle

Affiliation Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Carly J. Pierce

Affiliation Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Andreas Suhrbier

Andreas.Suhrbier@qimrberghofer.edu.au

Affiliation Inflammation Biology, and Cancer Drug Mechanism Laboratories, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Competing Interests

K. Skak is an employee of Leo Pharma. AS was a paid consultant for Leo Pharma in 2011. AS is an inventor on a series of patents covering ingenol mebutate (Picato), but receives no royalties or financial (or other) benefits as a result. These commercial affiliations do not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: K. Schroder K. Skak AS WS GB. Performed the experiments: TTL K. Schroder WS CP. Analyzed the data: K. Schroder AS. Contributed reagents/materials/analysis tools: K. Skak GB CP. Wrote the paper: AS.